Daraxonrasib Cracks KRAS but Exposes Limits of Single-Target Precision Oncology in Pancreatic Cancer

The Phase 3 RCT (n=500, post-progression metastatic pancreatic ductal adenocarcinoma) showed daraxonrasib extending median overall survival from 6.7 to 13.2 months versus chemotherapy, cutting death risk by 60%. This indirect mechanism—binding cyclophilin A to sequester active KRAS—sidesteps the smooth protein surface that defeated direct inhibitors for decades. Yet the MedicalXpress report underplays emerging resistance patterns already documented in G12C-selective agents such as sotorasib (NEJM 2021, n=38) and adagrasib (JCO 2022). Secondary KRAS mutations and bypass via PI3K or YAP signaling appeared within months in those trials; the same trajectory is likely here. The 86% rash rate and stomatitis also signal on-target epithelial toxicity not fully captured in short-term quality-of-life scores. Broader context reveals a pattern: indirect KRAS blockade may benefit the >90% of pancreatic tumors with non-G12C mutations, but combination strategies (e.g., with SHP2 or CDK4/6 inhibitors) will be required to prevent rapid escape. Cost-effectiveness and equitable access remain unaddressed, mirroring delays seen after KRAS G12C approvals.